Show simple item record

AuthorFuruya-Kanamori L.
AuthorDoi S.A.
AuthorOnitilo A.
AuthorAkhtar S.
Available date2022-05-31T19:01:29Z
Publication Date2020
Publication NameExpert Opinion on Drug Safety
ResourceScopus
Identifierhttp://dx.doi.org/10.1080/14740338.2020.1691167
URIhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075141265&doi=http://dx.doi.org/10.1080%2f14740338.2020.1691167&partnerID=40&md5=7483941d7d51fdd5712e055c0b9e3bd2
URIhttp://hdl.handle.net/10576/31873
AbstractObjectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize that the original studies may have produced exaggerated results because of the small baseline risks involved. Methods: A meta-analysis that included 71 trials, 8 different VEGFR-TKIs, and 11 adverse events were re-analyzed. The outcome of interest was re-defined as the complementary outcome (i.e. remaining free of an adverse event). The inverse variance heterogeneity model was used to pool the effect size. Results: VEGFR-TKIs decreased the risk of remaining free of hypertension by 7% (RR 0.93; 95%CI:0.88?0.97). Specific VEGFR-TKIs; pazopanib, regorafenib, and nintedanib were associated with a decrease risk of remaining free of an arterial thrombotic event (RR 0.96; 95%CI:0.93?0.99), thrombocytopenia (RR 0.91; 95%CI:0.89?0.93), and bleeding (RR 0.96; 95%CI:0.93?0.99) respectively. VEGFR-TKIs were not associated with the thrombotic event, myocardial infarction, stroke, venous thrombotic event, pulmonary embolism, left ventricular dysfunction, or QTc interval prolongation. Conclusion: VEGFR-TKIs are associated with a small increase in the risk of patients developing hypertension, arterial thrombotic events, thrombocytopenia, and bleeding. Previous studies overestimated the actual risk associated with VEGFR-TKIs by analyzing the outcome with the lower baseline risk.
Languageen
PublisherTaylor and Francis Ltd
Subjectaxitinib
lenvatinib
nintedanib
pazopanib
protein tyrosine kinase inhibitor
regorafenib
sorafenib
sunitinib
vandetanib
vasculotropin
angiogenesis inhibitor
protein kinase inhibitor
vasculotropin receptor
artery thrombosis
Article
bleeding
cardiovascular disease
cardiovascular risk
hematologic disease
human
hypertension
meta analysis
systematic review
thrombocytopenia
cardiovascular disease
hematologic disease
Angiogenesis Inhibitors
Cardiovascular Diseases
Hematologic Diseases
Humans
Protein Kinase Inhibitors
Receptors, Vascular Endothelial Growth Factor
TitleIs there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
TypeArticle
Pagination223-228
Issue Number2
Volume Number19
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record